Response
One must be cautious in analyzing the apparent sequential changes in hormone levels in the two treatment groups in the Valsartan Heart Failure Trial (Val-HeFT) because the analysis at each time point is compared with the baseline for that patient group, and the number of patients declines over time according to time of follow-up and dropouts. Sequential changes could be explored only in an analysis of "completers"-that is, patients who had measurements at each time point-and that would, of course, exclude patients who died. Such an analysis of the 1334 completers reveals that the suppression of aldosterone levels in the valsartan group compared with the placebo group is constant throughout follow-up, thus confirming that there is no "escape." On the other hand, there is a significant increase in aldosterone levels in both groups from 12 to 24 months. Therefore, a progressive increase over time, previously observed with B-type natriuretic peptide in Val-HeFT and with plasma norepinephrine in Val-HeFT and in previous trials, is consistent with the natural history of progressive heart failure.
As explained in our report, 1 the aldosterone data provide no obvious rationale for the use of aldosterone inhibitors in patients treated with valsartan. Nonetheless, the data do not exclude a benefit from blocking the residual circulating or tissue levels of aldosterone, an action through an alternative occupant of the receptor, or a long-term benefit by inhibiting the effect of the progressive increase in aldosterone levels over time.
